SG11201807374WA - Rna replicon for versatile and efficient gene expression - Google Patents
Rna replicon for versatile and efficient gene expressionInfo
- Publication number
- SG11201807374WA SG11201807374WA SG11201807374WA SG11201807374WA SG11201807374WA SG 11201807374W A SG11201807374W A SG 11201807374WA SG 11201807374W A SG11201807374W A SG 11201807374WA SG 11201807374W A SG11201807374W A SG 11201807374WA SG 11201807374W A SG11201807374W A SG 11201807374WA
- Authority
- SG
- Singapore
- Prior art keywords
- rna
- international
- rna replicon
- alphavirus
- a5atg
- Prior art date
Links
- 230000014509 gene expression Effects 0.000 title abstract 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 10
- 241000710929 Alphavirus Species 0.000 abstract 6
- 230000010076 replication Effects 0.000 abstract 5
- 108020003589 5' Untranslated Regions Proteins 0.000 abstract 4
- 108010026228 mRNA guanylyltransferase Proteins 0.000 abstract 4
- 239000012634 fragment Substances 0.000 abstract 3
- 101800000515 Non-structural protein 3 Proteins 0.000 abstract 2
- 108700026244 Open Reading Frames Proteins 0.000 abstract 2
- 108091081024 Start codon Proteins 0.000 abstract 2
- 101710172711 Structural protein Proteins 0.000 abstract 2
- 108700019146 Transgenes Proteins 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 101800000980 Protease nsP2 Proteins 0.000 abstract 1
- 101800001758 RNA-directed RNA polymerase nsP4 Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 229940070376 protein Drugs 0.000 abstract 1
- 230000014616 translation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2016/056165 WO2017162266A1 (en) | 2016-03-21 | 2016-03-21 | Rna replicon for versatile and efficient gene expression |
| PCT/EP2017/055808 WO2017162460A1 (en) | 2016-03-21 | 2017-03-13 | Rna replicon for versatile and efficient gene expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201807374WA true SG11201807374WA (en) | 2018-10-30 |
Family
ID=55587284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201807374WA SG11201807374WA (en) | 2016-03-21 | 2017-03-13 | Rna replicon for versatile and efficient gene expression |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US11168337B2 (pl) |
| EP (2) | EP3701959B1 (pl) |
| JP (2) | JP7121443B2 (pl) |
| KR (1) | KR102161607B1 (pl) |
| CN (2) | CN108884473B (pl) |
| AU (1) | AU2017236239B2 (pl) |
| BR (1) | BR112018068381A2 (pl) |
| CA (1) | CA3017272A1 (pl) |
| CY (1) | CY1125086T1 (pl) |
| DK (2) | DK3433369T3 (pl) |
| ES (2) | ES2906807T3 (pl) |
| HK (1) | HK1259449A1 (pl) |
| HR (1) | HRP20220044T1 (pl) |
| HU (2) | HUE059139T2 (pl) |
| IL (2) | IL261379B (pl) |
| LT (1) | LT3701959T (pl) |
| MX (1) | MX2018011383A (pl) |
| PL (2) | PL3433369T3 (pl) |
| PT (2) | PT3433369T (pl) |
| RS (1) | RS62864B1 (pl) |
| RU (1) | RU2748892C2 (pl) |
| SG (1) | SG11201807374WA (pl) |
| SI (2) | SI3433369T1 (pl) |
| WO (2) | WO2017162266A1 (pl) |
| ZA (1) | ZA201805519B (pl) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201710973D0 (en) | 2017-07-07 | 2017-08-23 | Avacta Life Sciences Ltd | Scaffold proteins |
| EP3681993A1 (en) * | 2017-09-13 | 2020-07-22 | BioNTech RNA Pharmaceuticals GmbH | Rna replicon for reprogramming somatic cells |
| US20200283497A1 (en) * | 2017-09-13 | 2020-09-10 | Biontech Cell & Gene Therapies Gmbh | Rna replicon for expressing at cell receptor or an artificial t cell receptor |
| TW202043256A (zh) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| EP3980059A1 (en) * | 2019-06-10 | 2022-04-13 | Infectious Disease Research Institute | Methods and compositions of astrovirus replicons |
| WO2021074695A1 (en) | 2019-10-16 | 2021-04-22 | Avacta Life Sciences Limited | PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES. |
| CN110890127B (zh) * | 2019-11-27 | 2024-02-23 | 山东大学 | 酿酒酵母dna复制起始区域识别方法 |
| JP2023508726A (ja) | 2019-12-31 | 2023-03-03 | エリクサージェン セラピューティクス，インコーポレイティド | 細胞及び組織への核酸及びタンパク質の温度ベースの一過性送達 |
| EP4103228A1 (en) | 2020-02-13 | 2022-12-21 | Institut Pasteur | Nucleic acid vaccine against the sars-cov-2 coronavirus |
| CA3171219A1 (en) | 2020-03-09 | 2021-09-16 | Arcturus Therapeutics, Inc. | Compositions and methods for inducing immune responses |
| WO2021213924A1 (en) * | 2020-04-22 | 2021-10-28 | BioNTech SE | Coronavirus vaccine |
| CA3181193A1 (en) * | 2020-06-04 | 2021-12-09 | Mario Perkovic | Rna replicon for versatile and efficient gene expression |
| GB202101299D0 (en) | 2020-06-09 | 2021-03-17 | Avacta Life Sciences Ltd | Diagnostic polypetides and methods |
| JP2024510610A (ja) * | 2021-03-19 | 2024-03-08 | ティバ バイオテック エルエルシー | 人工アルファウイルス由来ｒｎａレプリコン発現系 |
| WO2022228827A1 (en) | 2021-04-26 | 2022-11-03 | Institut Pasteur | Human neutralizing monoclonal antibodies against sars-cov-2 and uses thereof |
| WO2022234003A1 (en) | 2021-05-07 | 2022-11-10 | Avacta Life Sciences Limited | Cd33 binding polypeptides with stefin a protein |
| TW202334196A (zh) | 2021-10-07 | 2023-09-01 | 英商阿法克塔生命科學有限公司 | Pd-l1結合多肽 |
| WO2023057946A1 (en) | 2021-10-07 | 2023-04-13 | Avacta Life Sciences Limited | Serum half-life extended pd-l1 binding polypeptides |
| CA3234396A1 (en) | 2021-10-18 | 2023-04-27 | BioNTech SE | Modified replicable rna and related compositions and their use |
| AU2022372325A1 (en) | 2021-10-18 | 2024-05-02 | BioNTech SE | Methods for determining mutations for increasing modified replicable rna function and related compositions and their use |
| WO2023067126A1 (en) | 2021-10-22 | 2023-04-27 | BioNTech SE | Oligosaccharide compounds and complexes |
| EP4285932A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharide complexes and uses |
| WO2023067124A1 (en) | 2021-10-22 | 2023-04-27 | BioNTech SE | Disulfide oligosaccharide compounds and complexes |
| EP4285933A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharide complexes and uses |
| WO2023067123A1 (en) | 2021-10-22 | 2023-04-27 | BioNTech SE | Oligosaccharide complexes and uses |
| EP4286004A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Disulfide oligosaccharide compounds and complexes |
| EP4186528A1 (en) | 2021-11-30 | 2023-05-31 | BioNTech SE | Oligosaccharide complexes and uses |
| EP4169580A1 (en) | 2021-10-22 | 2023-04-26 | BioNTech SE | Oligosaccharide compounds and complexes |
| WO2023067125A1 (en) | 2021-10-22 | 2023-04-27 | BioNTech SE | Oligosaccharide complexes and uses |
| EP4169578A1 (en) | 2021-10-22 | 2023-04-26 | BioNTech SE | Oligosaccharide compounds and complexes |
| EP4286003A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharide compounds and complexes |
| EP4286394A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharide compounds and complexes |
| WO2023067121A1 (en) | 2021-10-22 | 2023-04-27 | BioNTech SE | Oligosaccharide compounds and complexes |
| EP4169534A1 (en) | 2021-10-22 | 2023-04-26 | BioNTech SE | Oligosaccharide complexes and uses |
| EP4169579A1 (en) | 2021-10-22 | 2023-04-26 | BioNTech SE | Disulfide oligosaccharide compounds and complexes |
| CN114639442B (zh) * | 2022-03-30 | 2024-01-30 | 中国农业科学院农业基因组研究所 | 一种基于单核苷酸多态性预测开放阅读框的方法及系统 |
| WO2023213378A1 (en) | 2022-05-02 | 2023-11-09 | BioNTech SE | Replicon compositions and methods of using same for the treatment of diseases |
| WO2023218243A1 (en) | 2022-05-12 | 2023-11-16 | Avacta Life Sciences Limited | Lag-3/pd-l1 binding fusion proteins |
| WO2023232747A1 (en) | 2022-05-30 | 2023-12-07 | BioNTech SE | Complexes for delivery of nucleic acids |
| WO2024056856A1 (en) | 2022-09-15 | 2024-03-21 | BioNTech SE | Systems and compositions comprising trans-amplifying rna vectors with mirna |
| WO2024068674A1 (en) | 2022-09-26 | 2024-04-04 | BioNTech SE | Nucleic acid complexes and uses thereof |
| WO2024084462A1 (en) | 2022-10-21 | 2024-04-25 | BioNTech SE | Nucleic acid complexes and uses thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL145221A0 (en) | 1999-03-09 | 2002-12-01 | Large Scale Biology Corp Unive | Multiple component rna vector system for expression of foreign sequences |
| US7045335B2 (en) | 2001-09-06 | 2006-05-16 | Alphavax, Inc. | Alphavirus replicon vector systems |
| KR101454842B1 (ko) | 2003-03-20 | 2014-11-04 | 알파벡스, 인크. | 개선된 알파바이러스 레플리콘 및 헬퍼 구축물 |
| WO2008119827A1 (en) * | 2007-04-02 | 2008-10-09 | Fit Biotech Oy | Transreplicase constructs |
| EA017740B1 (ru) | 2007-06-19 | 2013-02-28 | Борд Оф Сьюпервайзорз Оф Луизиана Стэйт Юниверсити Энд Эгрикалчурал Энд Мекэникал Колледж | Синтез и применение антиинвертированных фосфоротиоатных аналогов кэп-структуры матричной phk |
| EP2183368B1 (en) * | 2007-06-21 | 2016-08-10 | Alphavax, Inc. | Promoterless cassettes for expression of alphavirus structural proteins |
| EP2527367A1 (en) | 2007-08-20 | 2012-11-28 | Glaxo Group Limited | Production method |
| PL215513B1 (pl) | 2008-06-06 | 2013-12-31 | Univ Warszawski | Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka |
| DE102008061522A1 (de) | 2008-12-10 | 2010-06-17 | Biontech Ag | Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung |
| EP2281579A1 (en) | 2009-08-05 | 2011-02-09 | BioNTech AG | Vaccine composition comprising 5'-Cap modified RNA |
| EP3449910A1 (en) | 2010-07-06 | 2019-03-06 | GlaxoSmithKline Biologicals S.A. | Cationic oil-in-water emulsions |
| EP2590626B1 (en) | 2010-07-06 | 2015-10-28 | GlaxoSmithKline Biologicals SA | Liposomes with lipids having an advantageous pka-value for rna delivery |
| EP3542789A3 (en) | 2010-08-31 | 2020-01-01 | GlaxoSmithKline Biologicals SA | Lipids suitable for liposomal delivery of protein-coding rna |
| PT4043040T (pt) | 2010-08-31 | 2023-03-24 | Glaxosmithkline Biologicals Sa | Lipossomas pequenos para entrega de arn que codifica um imunogénio |
| PL3981427T3 (pl) | 2010-08-31 | 2022-09-19 | Glaxosmithkline Biologicals S.A. | Pegylowane liposomy do dostarczania rna kodującego immunogen |
| TR201903651T4 (tr) | 2010-10-11 | 2019-04-22 | Glaxosmithkline Biologicals Sa | Antijen uygulama platformları. |
| SG10201605500TA (en) | 2011-07-06 | 2016-08-30 | Novartis Ag | Cationic oil-in-water emulsions |
| JP2014520806A (ja) | 2011-07-06 | 2014-08-25 | ノバルティス アーゲー | Ｒｎａ分子の送達のための有用なｎ：ｐ比を有するリポソーム |
| US9655845B2 (en) | 2011-07-06 | 2017-05-23 | Glaxosmithkline Biologicals, S.A. | Oil-in-water emulsions that contain nucleic acids |
| SG10201602456WA (en) | 2011-08-31 | 2016-04-28 | Novartis Ag | Pegylated liposomes for delivery of immunogen-encoding rna |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| WO2014071963A1 (en) | 2012-11-09 | 2014-05-15 | Biontech Ag | Method for cellular rna expression |
| WO2016005004A1 (en) | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilization of poly(a) sequence encoding dna sequences |
-
2016
- 2016-03-21 WO PCT/EP2016/056165 patent/WO2017162266A1/en active Application Filing
-
2017
- 2017-03-13 KR KR1020187027294A patent/KR102161607B1/ko active IP Right Grant
- 2017-03-13 ES ES20156693T patent/ES2906807T3/es active Active
- 2017-03-13 CA CA3017272A patent/CA3017272A1/en active Pending
- 2017-03-13 HU HUE20156693A patent/HUE059139T2/hu unknown
- 2017-03-13 LT LTEP20156693.2T patent/LT3701959T/lt unknown
- 2017-03-13 PT PT177105285T patent/PT3433369T/pt unknown
- 2017-03-13 RS RS20220067A patent/RS62864B1/sr unknown
- 2017-03-13 EP EP20156693.2A patent/EP3701959B1/en active Active
- 2017-03-13 ES ES17710528T patent/ES2784711T3/es active Active
- 2017-03-13 WO PCT/EP2017/055808 patent/WO2017162460A1/en active Application Filing
- 2017-03-13 SG SG11201807374WA patent/SG11201807374WA/en unknown
- 2017-03-13 RU RU2018131966A patent/RU2748892C2/ru active
- 2017-03-13 MX MX2018011383A patent/MX2018011383A/es unknown
- 2017-03-13 EP EP17710528.5A patent/EP3433369B1/en active Active
- 2017-03-13 CN CN201780019155.1A patent/CN108884473B/zh active Active
- 2017-03-13 PL PL17710528T patent/PL3433369T3/pl unknown
- 2017-03-13 PT PT201566932T patent/PT3701959T/pt unknown
- 2017-03-13 DK DK17710528.5T patent/DK3433369T3/da active
- 2017-03-13 CN CN202210935299.4A patent/CN115927467A/zh active Pending
- 2017-03-13 HU HUE17710528A patent/HUE050350T2/hu unknown
- 2017-03-13 SI SI201730212T patent/SI3433369T1/sl unknown
- 2017-03-13 JP JP2018549313A patent/JP7121443B2/ja active Active
- 2017-03-13 BR BR112018068381A patent/BR112018068381A2/pt active Search and Examination
- 2017-03-13 SI SI201731043T patent/SI3701959T1/sl unknown
- 2017-03-13 US US16/086,157 patent/US11168337B2/en active Active
- 2017-03-13 DK DK20156693.2T patent/DK3701959T3/da active
- 2017-03-13 PL PL20156693T patent/PL3701959T3/pl unknown
- 2017-03-13 AU AU2017236239A patent/AU2017236239B2/en active Active
- 2017-03-13 HR HRP20220044TT patent/HRP20220044T1/hr unknown
-
2018
- 2018-08-17 ZA ZA201805519A patent/ZA201805519B/en unknown
- 2018-08-26 IL IL261379A patent/IL261379B/en unknown
-
2019
- 2019-02-01 HK HK19101854.2A patent/HK1259449A1/zh unknown
-
2021
- 2021-10-05 US US17/494,601 patent/US20220033852A1/en active Pending
-
2022
- 2022-01-26 CY CY20221100063T patent/CY1125086T1/el unknown
- 2022-03-03 IL IL291100A patent/IL291100B2/en unknown
- 2022-08-02 JP JP2022123058A patent/JP7465310B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201807374WA (en) | Rna replicon for versatile and efficient gene expression | |
| SG11201909777YA (en) | Modulatory polynucleotides | |
| SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
| SG11201811603WA (en) | Novel adeno-associated virus capsid proteins | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201407866XA (en) | Method for expression of heterologous proteins using a recombinant negative-strand rna virus vector | |
| SG11201809700YA (en) | Gdf15 fusion proteins and uses thereof | |
| SG11201909868YA (en) | Compositions and methods of treating huntington's disease | |
| SG11201809643UA (en) | Compositions and methods of treating huntington's disease | |
| SG11201803697SA (en) | Method for the economic manufacturing of metallic parts | |
| SG11201900400QA (en) | Bispecific antibody-like binding proteins specifically binding to cd3 and cd123 | |
| SG11201903514VA (en) | Novel cd47 monoclonal antibodies and uses thereof | |
| SG11201810048VA (en) | Tri-segmented pichinde viruses as vaccine vectors | |
| SG11201807573VA (en) | Methods for providing single-stranded rna | |
| SG11201909520VA (en) | Rna for treatment of autoimmune diseases | |
| SG11201907855QA (en) | Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2 | |
| SG11201909203WA (en) | Tissue selective transgene expression | |
| SG11201407595UA (en) | Generation of human ips cells by a synthetic self- replicative rna | |
| SG11201811554SA (en) | Antisense oligonucleotides for modulating htra1 expression | |
| SG11202000312UA (en) | Encapsulated polynucleotides and methods of use | |
| SG11201903042VA (en) | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome | |
| SG11201909957TA (en) | Engineered ligase variants | |
| SG11201408761VA (en) | Purification of iduronate-2-sulfatase | |
| SG11201408289UA (en) | Process for production of adipic acid from 1,6-hexanediol | |
| SG11201807062RA (en) | Anti-tnfalpha-antibodies and functional fragments thereof |